Cannabis Chronic Pain Clinical Trials: Evidence, Status, and Outlook

Executive summary

A trial billed as the first of its kind in the United States has opened in New York to test cannabis for chronic pain, and it lands in the middle of the most consequential federal cannabis policy shift in 50 years. Cannabis Equipment News reported the news on October 6, 2026. This page tracks the trial and the research ecosystem around it.

The headline does not settle several details: sponsor, enrollment, dosing, comparator arm and funding. CannIntel will add them once a protocol or registry entry is confirmed. "First" also needs a qualifier. U.S. academic groups, including the University of California's Center for Medicinal Cannabis Research, have run controlled pain trials for roughly two decades. The novelty is more likely in design, setting or product type than in being the first U.S. pain trial ever.

Chronic pain is the most common reason patients enroll in state medical programs, yet the evidence base is thinner than the market implies. The National Academies of Sciences, Engineering, and Medicine concluded in 2017 that there is substantial or conclusive evidence cannabis or cannabinoids are effective for chronic pain in adults. Later systematic reviews found the average benefit modest and the trial quality uneven.

Federal barriers have constrained better trials. Marijuana remains in Schedule I under 21 U.S.C. § 812, researchers have historically depended on a narrow federal supply, and trial products rarely resemble what patients buy in dispensaries. For operators, the key question is whether New York's trial produces data on chemotypes and formulations that regulators, payers and physicians will accept.

Why this matters

Chronic pain affects tens of millions of Americans, drives a large share of medical cannabis enrollment, and sits at the center of the opioid-substitution debate, so credible trial data shapes patients, payers and policy at once.

According to a 2023 CDC Morbidity and Mortality Weekly Report, about 20.9% of U.S. adults (an estimated 51.6 million people) had chronic pain in 2021, and about 6.9% (17.1 million) had high-impact chronic pain that limits life or work activities. A 2011 Institute of Medicine report put the annual economic cost of pain in the United States at $560 billion to $635 billion, counting medical costs and lost productivity.

Stakeholders

• Patients: People with neuropathic, musculoskeletal and other chronic pain who want alternatives or adjuncts to opioids, NSAIDs and gabapentinoids.
• Clinicians: Physicians and nurse practitioners who certify patients in programs like New York's and lack standardized dosing guidance.
• Operators and MSOs: Licensed companies that want evidence to support medical positioning, clinical partnerships and eventual payer interest.
• Regulators: The FDA, DEA, NIH and state agencies such as New York's Office of Cannabis Management (OCM).
• Insurers and employers: They currently cover almost none of the cost, and coverage depends on evidence of the kind this trial aims to generate.

For investors, trial data can shift the sector's narrative from adult-use commodity to regulated therapeutic. That distinction matters for pricing power, product design, and how federal lawmakers treat the industry if marijuana moves to Schedule III.

Background and history

Cannabis pain research has advanced in fits and starts for 40 years, held back by Schedule I status, a restricted federal supply, and a mismatch between trial products and retail products.

1970–1985: Schedule I and the first approved cannabinoids

The Controlled Substances Act of 1970 placed marijuana in Schedule I, defined as a drug with high abuse potential and no accepted medical use. That classification triggered DEA registration, secure storage and protocol approval for any researcher. In 1985 the FDA approved dronabinol (Marinol), a synthetic THC capsule, for chemotherapy-induced nausea. Nabilone (Cesamet) followed. Neither was approved for pain, and neither resembled whole-plant cannabis.

1996–1999: State programs and the first major review

California voters passed Proposition 215 in 1996, creating the first modern state medical cannabis program. In 1999 the Institute of Medicine published "Marijuana and Medicine," which saw therapeutic promise in cannabinoids for pain and called for rigorous trials. States then moved faster than federal research did, so patients used cannabis for pain years before robust trial data existed.

2000–2010: California's research center and the supply bottleneck

California created the Center for Medicinal Cannabis Research (CMCR) at UC San Diego, funded through state legislation, to run controlled trials. Its studies, along with Canadian work, produced early randomized evidence in neuropathic pain, including HIV-associated neuropathy and post-traumatic neuropathic pain. Meanwhile, researchers needing federal-grade cannabis had one source: the University of Mississippi, under a NIDA contract. In the mid-2000s, University of Massachusetts Amherst professor Lyle Craker sought a DEA license to grow research cannabis. An administrative law judge recommended granting it in 2007, and the DEA denied the application in 2009.

2005–2014: Pharmaceutical cannabinoids abroad

Canada approved the oromucosal spray nabiximols (Sativex) for neuropathic pain in multiple sclerosis in 2005. Other countries followed for MS spasticity. The U.S. never approved Sativex, though sponsors ran cancer-pain trials. New York enacted the Compassionate Care Act in July 2014, and its medical program launched in January 2016 with a restrictive condition list and limited product forms.

2016–2018: The DEA supply promise and the National Academies

In 2016 the DEA announced a policy to register additional growers for research cannabis. It did not finalize any licenses for years, and applicants waited through 2019 and beyond. In January 2017 the National Academies issued its landmark review, concluding there was substantial or conclusive evidence for chronic pain in adults, and moderate evidence for some other conditions. The 2018 Farm Bill (Agriculture Improvement Act of 2018) legalized hemp under 0.3% delta-9 THC, and the FDA approved Epidiolex (plant-derived CBD) for certain seizure disorders in 2018, the first plant-derived cannabinoid drug approval of the modern era. New York subsequently added chronic pain as a qualifying condition, which made it one of the largest drivers of enrollment.

2018–2021: Skeptical evidence

A 2018 Cochrane review of cannabinoids for neuropathic pain graded most of the evidence low quality. The same year, Australia's POINT cohort study, published in Lancet Public Health, found that among people with chronic non-cancer pain prescribed opioids, cannabis use was not associated with reduced pain severity or reduced opioid dose. A 2021 BMJ systematic review led by Li Wang and colleagues found medical cannabis offered small to very small improvements in pain relief, physical functioning and sleep quality, with some risk of dizziness and nausea. The International Association for the Study of Pain's 2021 task force said the evidence did not support endorsing general use for pain. New York's Marihuana Regulation and Taxation Act (MRTA) passed March 31, 2021, and created the OCM.

2022–2025: Research law and rescheduling

President Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act (Public Law 117-215) in December 2022. It streamlined researcher access and directed the DEA to register more manufacturers. New York's adult-use sales began on December 29, 2022. In August 2023 the Department of Health and Human Services recommended moving marijuana to Schedule III. In May 2024 the DEA published a notice of proposed rulemaking (NPRM) to do so, and an administrative law judge (ALJ) hearing process followed but stalled in early 2025. In December 2025 President Trump signed an executive order directing the Attorney General to expedite rescheduling to Schedule III. Readers should verify the current final-rule status, because it changes the economics described below.

2026: New York's trial

On October 6, 2026, Cannabis Equipment News reported that New York hosts the first U.S. trial of its kind for using cannabis to treat chronic pain. This hub will record protocol details as they become public.

Key players

The cast spans federal gatekeepers, state agencies, academic centers, licensed operators and organized advocates and opponents, and each controls a different lever for pain research.

FDA

The FDA regulates drug development through the Investigational New Drug (IND) process under 21 CFR Part 312. It has said it supports well-controlled cannabis research and has issued guidance on cannabis-derived compound studies. A trial seeking labeled indications must go through the FDA; a state-sanctioned observational or pragmatic study may not.

DEA

The DEA registers researchers and manufacturers handling Schedule I substances and approves protocols. It controls how quickly new growers come online and whether rescheduling takes effect. A final